Patient Condition
Retired lawyer, recent memory has suffered a serious decline, affecting social activities. Pitié-Salpêtrière hospital assessment showed an MMSE score of 19 points (transition from mild to moderate), and early AD was confirmed by cerebrospinal fluid and PET examinations.
Treatment Timeline
| Phase | Details | Date |
|---|
| Early diagnosis and biomarker baseline | | |
| Aducanumab anti-A β clearance therapy | | |
| Semorinemab anti-tau combination therapy | | |
| Maintenance treatment and cognitive function protection | | |
Treatment Outcome
| before | MMSE score of 19 points, severe decline in recent memory, social withdrawal, and decreased quality of life |
|---|
| after | MMSE score of 24 points (improvement of 5 points), improved memory, resumed social activities, improved quality of life |
|---|
| highlight | Social function recovered significantly, and patients resumed participation in community activities |
|---|